Articles From: Cellular Dynamics to Present at 2014 Stem Cell Meeting on the Mesa to Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection


MADISON, Wis., Oct.
Sign-up for Cellular Dynamics to Present at 2014 Stem Cell Meeting on the Mesa investment picks
LAWRENCEVILLE, N.J. , Oct.
Sign-up for Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors investment picks
Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study Study Designed to Support Registration in Major Liver Cancer Markets Worldwide LAWRENCEVILLE, N.J. , Sept.
Sign-up for Celsion Announces Enrollment of First Patient in Global Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer investment picks
Highly Attended Celsion-Sponsored Symposium on Current Concepts for Treating Intermediate HCC included: New Paradigm in Staging HCC Patients; Phase III Studies in HCC; and Advances in Image Guided Radiofrequency Ablation Professor Poon's presentation, titled " New Paradigms in Staging HCC: BCLC vs.
Sign-up for Celsion Announces Highlights from Three Presentations Given at the International Liver Cancer Association 2014 Annual Conference investment picks
ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Refractory Patients LAWRENCEVILLE, N.J. , July 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia.
Sign-up for Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer investment picks
LAWRENCEVILLE, N.J. , Oct.
Sign-up for Celsion Announces The Unexpected Passing of Max E. Link, Ph.D., Chairman of the Board investment picks
Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival Data Continues to Validate Phase III OPTIMA Study Design LAWRENCEVILLE, N.J. , July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC). As of June 30, 2014 , the latest quarterly Overall Survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the study patients), the combination of ThermoDox® and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone.
Sign-up for Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer investment picks
ADVISORY, July 15, 2014 (GLOBE NEWSWIRE) -- What: Celsion Corporation (Nasdaq:CLSN) , a leading oncology drug development company, will visit the NASDAQ MarketSite in Times Square.
Sign-up for Celsion Corporation (NASDAQ: CLSN) to Ring The NASDAQ Stock Market Closing Bell investment picks
Advances Ongoing Collaboration with Brigham and Women's Hospital, Harvard Medical School LAWRENCEVILLE, N.J. , July 21, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) , a leading oncology drug development company, announced today that its ongoing collaboration with Dr.
Sign-up for Celsion Corporation Announces $1 Million NIH, NIBIB - Career Development Award Grant for Glioblastoma Research with ThermoDox® and HIFU investment picks
Potential in Life Science Research Validates Newly Acquired Technology Platforms for the Delivery of Plasmid DNA and a Variety of RNA in Mammalian Cells LAWRENCEVILLE, N.J. , July 15, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) , a leading oncology drug development company, today announced initiation of sales of its proprietary reagent products for life science research.
Sign-up for Celsion Corporation Announces Commercialization of Reagent Products investment picks
2014/8/7
Company Completes Acquisition of EGEN, Inc. Company to Hold Conference Call Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , Aug.
Sign-up for Celsion Corporation Reports Second Quarter 2014 Financial Results investment picks
Conference Call on Thursday, August 7, 2014 LAWRENCEVILLE, N.J. , July 31, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its second quarter 2014 financial results at 11:00 a.m. EDT on Thursday, August 7, 2014 .
Sign-up for Celsion Corporation to Hold Second Quarter 2014 Financial Results investment picks
Company Commemorates its Transformative Acquisition of EGEN, Inc. and the Initiation of the Phase III Pivotal OPTIMA Study in Primary Liver Cancer LAWRENCEVILLE, N.J. , July 14, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) , a leading oncology drug development company, announced today that the Company will ring the NASDAQ Stock Market closing bell on Wednesday, July 16, 2014 in Times Square, New York, NY .
Sign-up for Celsion Corporation to Ring the NASDAQ Stock Market Closing Bell on July 16, 2014 investment picks
ThermoDox® Combined with Mild Local Hyperthermia is Safe and Produces Compelling Objective Local Responses in RCW Breast Cancer Patients Reinforces Current Phase II Interim Response Rates in Heavily Pretreated Patients, Further Supporting Continued Development Plans LAWRENCEVILLE, N.J. , Sept.
Sign-up for Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on ThermoDox® in Recurrent Chest Wall Breast Cancer Published in the International Journal of Hyperthermia investment picks
LAWRENCEVILLE, N.J. , Aug.
Sign-up for Celsion to Present at the Rodman & Renshaw 16th Annual Healthcare Conference investment picks
2014/8/8
BOCA RATON, Fla., Aug.
Sign-up for Celsius Holdings, Inc. Reports Second Quarter 2014 Financial Results investment picks
2014/8/4
BOCA RATON, Fla., Aug.
Sign-up for Celsius(R) Launches Fitness Challenge With TriStar Motorsports and NASCAR Driver Blake Koch investment picks
2014/7/28
BOCA RATON, Fla., July 28, 2014 (GLOBE NEWSWIRE) -- Celsius Holdings, Inc., (Other OTC:CELH) the creator and marketer of Celsius ® , the world's first Negative Calorie beverage backed by clinical science, in partnership with global music superstar Flo Rida, is excited to announce the launch of Flo Fusion with MetaPlus®, a pre-workout powder now available in GNC retailers nationwide.
Sign-up for Celsius(R) Launches Flo Fusion(TM) Pre-Workout Powder in GNC Retailers Nationwide investment picks
2014/7/22
BOCA RATON, Fla., July 22, 2014 (GLOBE NEWSWIRE) -- Celsius Holdings, Inc., (Other OTC:CELH) the creator and marketer of Celsius ® , the world's first Negative Calorie beverage backed by clinical science, is excited to announce its endorsement agreement with Two Time Formula One World Champion and Two Times Winner of the Indy 500 Race, Racecar Driver Emerson Fittipaldi.
Sign-up for Celsius(R) Signs World Champion Racecar Driver Emerson Fittipaldi to Endorsement Agreement investment picks
2014/7/24
Cementos Pacasmayo S.A.A. and subsidiaries (NYSE:CPAC; BVL:CPACASC1) (“the Company” or “Cementos Pacasmayo”) a Peruvian cement company, announced today its consolidated results for the second quarter (“2Q14”) and six-month (“6M14”) ended June 30, 2014.
Sign-up for Cementos Pacasmayo S.A.A. Announces Consolidated Results for Second Quarter 2014 investment picks
2014/7/21
LIMA, Peru , July 21, 2014 /PRNewswire/ -- Cementos Pacasmayo S.A.A. (NYSE: CPAC; BVL: CPACASC1) ("Cementos Pacasmayo" or "the Company") announced today that it will host its Second Quarter 2014 earnings conference call & audio webcast: Friday, July 25, 2014 at 11:00 a.m. New York Time/ 10:00 a.m. Lima Time.
Sign-up for Cementos Pacasmayo to Host Second Quarter 2014 Earnings Conference Call & Audio Webcast investment picks
2014/10/2
CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE: CX) announced today the expiration of its previously announced cash tender offer (the “Tender Offer”) to purchase up to U.S.$1,175 million of the 9.000% Senior Secured Notes due 2018 (the “2018 Notes”) issued by CEMEX and the 9.250% Senior Secured Notes due 2020 (the “2020 Notes” and, together with the 2018 Notes, the “Notes”) issued by CEMEX España, S.A., acting through its Luxembourg Branch.
Sign-up for CEMEX Announces Expiration and Final Settlement of its Tender Offer for Certain Senior Secured Notes investment picks
2014/8/14
CEMEX, S.A.B. de C.V. ("CEMEX") (NYSE: CX) announced today that its subsidiary, CEMEX Latam Holdings, S.A. ("CLH") (BVC: CLH), will begin the construction of a cement plant in Colombia.
Sign-up for CEMEX Announces New CLH Cement Plant in Colombia investment picks
2014/9/4
CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE:CX) announced today its intention to offer senior secured notes in one or more series denominated in Euros (the “Euro Notes”), subject to market and other conditions.
Sign-up for CEMEX Announces Offering of Senior Secured Notes investment picks
2014/9/26
CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE: CX) announced today the pricing of its private offering of 200,000 Contingent Convertible Units, each with a stated amount of U.S.$1,000. The Contingent Convertible Units are intended to finance payment of the principal amount of U.S.$200 million of CEMEX’s 4.875% Convertible Subordinated Notes due 2015 (the “2015 Existing Convertible Notes”) that mature without conversion.
Sign-up for CEMEX Announces Pricing of U.S.$200 Million in Contingent Convertible Units investment picks
2014/9/30
CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE: CX) announced today that it has entered into a new credit agreement for U.S.$1.35 billion (the "Credit Agreement"), with nine of the main lending banks from its Facilities Agreement dated September 17, 2012 (as amended from time to time, the "Facilities Agreement".) The main terms of the new Credit Agreement, which represent an improvement over the main terms of the existing Facilities Agreement, are as follows: An average 4-year term with equal semi-annual payments of principal of 20% each, beginning on the third anniversary of the Credit Agreement and with the last payment on September 2019.
Sign-up for CEMEX Obtains New Bank Loan under Improved Conditions investment picks
2014/7/18
CEMEX, S.A.B. de C.V. ("CEMEX") (NYSE: CX), announced today that consolidated net sales reached U.S.$4.2 billion during the second quarter of 2014, an increase of 4% versus the comparable period in 2013.
Sign-up for CEMEX Reports Second-Quarter 2014 Results investment picks
CHAPEL HILL, N.C., Sept.
Sign-up for Cempra Completes Enrollment of Solitaire-Oral Phase 3 Trial investment picks
- Qualified Infectious Disease Product (QIDP) Granted for Solithromycin Capsules by the FDA - CHAPEL HILL, N.C., Aug.
Sign-up for Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Cellular Dynamics to Present at 2014 Stem Cell Meeting on the Mesa to Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices